The real pros of Wegovy, based on clinical evidence

What the trial data actually showed about weight loss

The STEP 1 results are the natural starting point, because they're what underpins the UK licence. Around 1,961 adults with obesity or overweight plus at least one weight-related condition took part; those on semaglutide 2.4mg lost an average of roughly 15% of their starting weight, compared with about 2.4% on placebo. That gap is meaningful. A participant starting at 100kg would, on average, lose around 15kg over just over a year, enough to move blood pressure, cholesterol and joint load in clinically relevant directions.

One misconception worth clearing up gently: some people assume Wegovy is mainly for people who want to lose a modest amount of weight for cosmetic reasons. The licence, and the people who took part in the trials, tell a different story. STEP 1 focused on adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure or type 2 diabetes, the same population NICE's appraisal of semaglutide (TA875) considered when recommending it within specialist services.

Results do vary between individuals, and clinical trials measure averages. Some participants lost considerably more than 15%; others less. A prescriber can help set realistic expectations based on your health profile rather than the headline number alone. You can read more about how Wegovy works in practice on our Wegovy overview page.

Why the cardiovascular licence matters for people with heart disease

Beyond weight loss, Wegovy holds a UK authorisation that semaglutide's diabetes sibling Ozempic does not carry for this population: reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity or overweight who also have established cardiovascular disease. That makes it one of the very few weight-loss medicines with a proven cardiovascular safety and efficacy profile in this group, not just a weight-number benefit.

For clinicians treating patients who sit at the intersection of excess weight and heart disease, this is significant. It means prescribing Wegovy can target two problems simultaneously, which changes the conversation from aesthetics to genuine disease management. The NHS England guidance on weight-management injections addresses this dual role directly.

This is also why the medicine is prescription-only and assessed individually. Someone with the right cardiovascular profile may find this aspect of Wegovy's evidence profile is as relevant as the weight-loss data, and that conversation belongs with a prescriber rather than a search engine. If you'd like to understand how different weight-loss treatments compare on this front, our semaglutide information page goes into more depth on the pharmacology.

Practical advantages: schedule, pen format and the newer 7.2mg option

One of the more underrated pros is simply the dosing format. Once a week, same day, one pen, that's the routine. The pre-filled injection pen is designed for self-administration in the abdomen, thigh or upper arm; most people adjust to it within the first few weeks. Compare that to a twice-daily tablet with strict food-and-timing rules, and the weekly injection is often the lower-burden option for people managing busy lives.

The treatment starts at 0.25mg and escalates gradually, roughly every four weeks, to the standard 2.4mg maintenance dose. That staged approach is deliberate: it gives the body time to adjust and keeps side effects manageable for most people. In January 2026 the MHRA also approved a higher 7.2mg dose, with a dedicated single-dose pen following in April 2026, offering an option for people who tolerate the 2.4mg well but want to explore whether a higher dose moves the needle further. Which dose and format applies to you is always a clinical decision; specific availability is confirmed at consultation.

For a fuller look at what the treatment involves day to day, the Wegovy dosing guide covers the schedule in plain language. And if you're weighing this against the alternative, the pros and cons of Wegovy page puts both sides alongside each other so you can read them together. For broader context on how Wegovy sits within the available options, our weight-loss treatment overview is a useful reference before speaking to a prescriber.

Cost, access, and making sense of the pros in context

Understanding the clinical pros is one thing; knowing how to access the medicine lawfully is another. Wegovy is a prescription-only medicine. NICE recommends it within specialist weight management services, which means NHS access typically involves a referral and a waiting list. Private routes through a regulated online pharmacy remove both barriers, though they come at a cost, and that cost varies considerably between providers depending on what's included.

Our detailed pros and cons guide for weight loss covers the financial side honestly, including what questions to ask any provider about what their headline price actually includes. It's worth reading before you commit. If you're still forming a view on whether Wegovy is the right fit or whether another licensed option might suit you better, the side-by-side advantages and disadvantages page addresses that directly.

Our clinical team reviews every consultation personally, a prescriber reads your answers, not software. If you'd like to understand whether you're likely to be eligible, the FAQs page covers common eligibility questions clearly. When you're ready to take the next step, you can start your free consultation and have your answers reviewed the same day.